MDT - Medtronic plc
Health CarePrice History
About
Company Overview
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients in the United States, Ireland, and internationally. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves, and percutaneous coronary intervention products, percutaneous angioplasty balloons, and other products. The Neuroscience Portfolio segment offers medical devices and implants, biologic solutions, spinal cord stimulation and brain modulation systems, implantable drug infusion systems, and interventional products, as well as nerve ablation system under the Accurian name. The segment offers its products for spinal surgeons, neurosurgeons, neurologists, pain management specialists, anesthesiologists, orthopedic surgeons, urologists, urogynecologists, and interventional radiologists, as well as ear, nose, and throat specialists, and energy surgical instruments. The Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure and electrosurgery products, AI-powered surgical video and analytics platform, robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology products, gastrointestinal and hepatologic diagnostics and therapies, and therapies to treat diseases and conditions, and patient monitoring and airway management products. The Diabetes Operating Unit segment provides insulin pumps and consumables, continuous glucose monitoring systems and sensors, and InPen, a smart insulin pen. Medtronic plc was founded in 1949 and is headquartered in Galway, Ireland.
Price
$86.65
52-Week Range
Dividend Yield
3.31%
Dividend Score
B
Dividend
Valuation
Profitability
Financial Health
Cash Flow
Analyst Consensus
25 analysts
Dividend Growth
Most Recent Annual Growth
1.43%
3-Year Avg Growth
1.96%
5-Year Avg Growth
4.46%
Annual Dividends
Year-over-Year Growth
Recent Dividend History
| Ex-Dividend Date | Amount |
|---|---|
| Mar 27, 2026 | $0.7100 |
| Dec 26, 2025 | $0.7100 |
| Sep 26, 2025 | $0.7100 |
| Jun 27, 2025 | $0.7100 |
| Mar 28, 2025 | $0.7000 |
| Dec 27, 2024 | $0.7000 |
| Sep 27, 2024 | $0.7000 |
| Jun 28, 2024 | $0.7000 |
| Mar 21, 2024 | $0.6900 |
| Dec 19, 2023 | $0.6900 |
| Sep 21, 2023 | $0.6900 |
| Jun 22, 2023 | $0.6900 |
| Mar 23, 2023 | $0.6800 |
| Dec 20, 2022 | $0.6800 |
| Sep 22, 2022 | $0.6800 |
| Jun 23, 2022 | $0.6800 |
| Mar 24, 2022 | $0.6300 |
| Dec 21, 2021 | $0.6300 |
| Sep 23, 2021 | $0.6300 |
| Jun 24, 2021 | $0.6300 |